m123456, yes off label use will start for PD perhaps immediately if BT434 will get to the pharmacy, perhaps also for AD. But to get PBT434 to millions of patients you need Ph 3 studies. Few thousands MSA and off label patients will make it possible, IMO.
Ann: Orphan Designation for PBT434 for treatment of MSA, page-10
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $17.43K | 5.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 74 | 107941696 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 1179951 | 2 |
View Market Depth
| Last trade - 15.31pm 07/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |